The Preeclampsia Diagnostics Market has shown notable growth, valued at USD 1.07 billion in 2022. Projections suggest modest expansion, with expectations reaching USD 1.24 billion by 2030. This growth reflects the ongoing need for effective diagnostic tools to identify and manage preeclampsia, a potentially life-threatening condition that affects pregnant individuals. With an anticipated compound annual growth rate (CAGR) of 2.4% over the forecast period from 2023 to 2030, the market is poised for gradual development, driven by factors such as increasing maternal age, rising prevalence of obesity, and improvements in diagnostic techniques aimed at early detection and intervention to mitigate the risks associated with preeclampsia.